{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:16:38Z","timestamp":1791000998453,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sialyltransferases transfer sialic acid to nascent oligosaccharides and are upregulated in cancer. The inhibition of sialyltransferases is emerging as a potential strategy to prevent metastasis in several cancers, including ovarian cancer. ST3GAL1 is a sialyltransferase that catalyzes the transfer of sialic acid from cytidine monophosphate-sialic acid to galactose-containing substrates and is associated with cancer progression and chemoresistance. However, the function of ST3GAL1 in ovarian cancer is uncertain. Herein, we use qRT-PCR, western blotting, and immunohistochemistry to assess the expression of ST3GAL1 in ovarian cancer tissue and cell lines and investigate whether it influences resistance to paclitaxel in vitro and in a mouse xenograft model. We found that ST3GAL1 is upregulated in ovarian cancer tissues and in the ovarian cancer cell lines SKOV-3 and OVCAR3 but downregulated in A2780 ovarian cancer cells. Overexpression of ST3GAL1 in A2780 cells increases cell growth, migration, and invasion whereas ST3GAL1 knockdown in SKOV-3 cells decreases cell growth, migration, and invasion. Furthermore, overexpression of ST3GAL1 increases resistance to paclitaxel while downregulation of ST3GAL1 decreases resistance to paclitaxel in vitro, and overexpression of ST3GAL1 increases tumorigenicity and resistance to paclitaxel in vivo. Transforming growth factor-\u03b21 can increase ST3GAL1 expression and induce ovarian cell epithelial\u2013mesenchymal transition (EMT). However, knockdown of ST3GAL1 inhibits EMT expression. Taken together, our findings have identified a regulatory mechanism involving ST3GAL1 in ovarian cancer. ST3GAL1 may be a promising target for overcoming paclitaxel resistance in ovarian carcinoma.<\/jats:p>","DOI":"10.1038\/s41419-018-1101-0","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T07:38:14Z","timestamp":1540885094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":164,"title":["Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-\u03b21-induced EMT and confers paclitaxel resistance in ovarian cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Xin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congjian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"1101_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","volume":"472","author":"J Permuth-Wey","year":"2009","unstructured":"Permuth-Wey, J. & Sellers, T. A. Epidemiology of ovarian cancer. Methods Mol. Biol. 472, 413\u2013437 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1101_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.clinthera.2018.01.012","volume":"40","author":"MH Vetter","year":"2018","unstructured":"Vetter, M. H. & Hays, J. L. Use of targeted therapeutics in epithelial ovarian cancer: a review of current literature and future directions. Clin. Ther. 40, 361\u2013371 (2018).","journal-title":"Clin. Ther."},{"key":"1101_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.14336\/AD.2017.0607","volume":"8","author":"L Tortorella","year":"2017","unstructured":"Tortorella, L. et al. Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments. Aging Dis. 8, 677\u2013684 (2017).","journal-title":"Aging Dis."},{"key":"1101_CR4","doi-asserted-by":"crossref","unstructured":"Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).","DOI":"10.1038\/nature10166"},{"key":"1101_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5732\/cjc.014.10284","volume":"34","author":"Y Sun","year":"2015","unstructured":"Sun, Y. et al. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin. J. Cancer 34, 28\u201340 (2015).","journal-title":"Chin. J. Cancer"},{"key":"1101_CR6","doi-asserted-by":"publisher","first-page":"19257","DOI":"10.3390\/ijms140919257","volume":"14","author":"P Brachova","year":"2013","unstructured":"Brachova, P., Thiel, K. W. & Leslie, K. K. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int. J. Mol. Sci. 14, 19257\u201319275 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"1101_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin, L. A. et al. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol. 120, 612\u2013618 (2012).","journal-title":"Obstet. Gynecol."},{"key":"1101_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0300-9084(01)01301-3","volume":"83","author":"A Harduin-Lepers","year":"2001","unstructured":"Harduin-Lepers, A. et al. The human sialyltransferase family. Biochimie 83, 727\u2013737 (2001).","journal-title":"Biochimie"},{"key":"1101_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/glycob\/cwv097","volume":"26","author":"OM Pearce","year":"2016","unstructured":"Pearce, O. M. & Laubli, H. Sialic acids in cancer biology and immunity. Glycobiology 26, 111\u2013128 (2016).","journal-title":"Glycobiology"},{"key":"1101_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10555-012-9359-7","volume":"31","author":"MJ Schultz","year":"2012","unstructured":"Schultz, M. J., Swindall, A. F. & Bellis, S. L. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastas-. Rev. 31, 501\u2013518 (2012).","journal-title":"Cancer Metastas-. Rev."},{"key":"1101_CR11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053\u20131064 (2010).","journal-title":"Am. J. Pathol."},{"key":"1101_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/med.21407","volume":"37","author":"R Szabo","year":"2017","unstructured":"Szabo, R. & Skropeta, D. Advancement of sialyltransferase inhibitors: therapeutic challenges and opportunities. Med. Res. Rev. 37, 219\u2013270 (2017).","journal-title":"Med. Res. Rev."},{"key":"1101_CR13","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1016\/j.bbagen.2014.06.006","volume":"1840","author":"F Dall\u2019Olio","year":"2014","unstructured":"Dall\u2019Olio, F., Malagolini, N., Trinchera, M. & Chiricolo, M. Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. Biochim. Biophys. Acta 1840, 2752\u20132764 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1101_CR14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/glycob\/9.12.1307","volume":"9","author":"J Burchell","year":"1999","unstructured":"Burchell, J. et al. Analpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 9, 1307\u20131311 (1999).","journal-title":"Glycobiology"},{"key":"1101_CR15","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1038\/onc.2016.53","volume":"35","author":"L zhang","year":"2016","unstructured":"zhang, L. et al. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. Oncogene 35, 5010\u20135020 (2016).","journal-title":"Oncogene"},{"key":"1101_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1242\/jcs.100115","volume":"126","author":"M Canel","year":"2013","unstructured":"Canel, M., Serrels, A., Frame, M. C. & Brunton, V. G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J. Cell Sci. 126, 393\u2013401 (2013).","journal-title":"J. Cell Sci."},{"key":"1101_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502\u2013516 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"1101_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1517\/13543784.2015.1072168","volume":"24","author":"C Marchetti","year":"2015","unstructured":"Marchetti, C., Ledermann, J. A. & Benedetti Panici, P. An overview of early investigational therapies for chemoresistant ovarian cancer. Expert. Opin. Investig. Drugs 24, 1163\u20131183 (2015).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1101_CR19","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","volume":"29","author":"SS Li","year":"2018","unstructured":"Li, S. S., Ma, J. & Wong, A. S. T. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism. J. Gynecol. Oncol. 29, e32 (2018).","journal-title":"J. Gynecol. Oncol."},{"key":"1101_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szakacs","year":"2006","unstructured":"Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1101_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","volume":"31","author":"A Kim","year":"2012","unstructured":"Kim, A., Ueda, Y., Naka, T. & Enomoto, T. Therapeutic strategies in epithelial ovarian cancer. J. Exp. Clin. Cancer Res. 31, 14 (2012).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1101_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364\u2013378 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"1101_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1124\/pr.111.005637","volume":"64","author":"DW Shen","year":"2012","unstructured":"Shen, D. W., Pouliot, L. M., Hall, M. D. & Gottesman, M. M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64, 706\u2013721 (2012).","journal-title":"Pharmacol. Rev."},{"key":"1101_CR24","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/jnci\/88.18.1308","volume":"88","author":"CG Milross","year":"1996","unstructured":"Milross, C. G. et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88, 1308\u20131314 (1996).","journal-title":"J. Natl. Cancer Inst."},{"key":"1101_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0006-2952(97)83383-7","volume":"53","author":"H Parekh","year":"1997","unstructured":"Parekh, H., Wiesen, K. & Simpkins, H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol. 53, 461\u2013470 (1997).","journal-title":"Biochem. Pharmacol."},{"key":"1101_CR26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1172\/JCI119642","volume":"100","author":"M Kavallaris","year":"1997","unstructured":"Kavallaris, M. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100, 1282\u20131293 (1997).","journal-title":"J. Clin. Invest."},{"key":"1101_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8419","volume":"6","author":"TA Ince","year":"2015","unstructured":"Ince, T. A. et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun. 6, 7419 (2015).","journal-title":"Nat. Commun."},{"key":"1101_CR28","first-page":"5379","volume":"43","author":"TC Hamilton","year":"1983","unstructured":"Hamilton, T. C. et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43, 5379\u20135389 (1983).","journal-title":"Cancer Res."},{"key":"1101_CR29","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/j.1349-7006.2007.00550.x","volume":"98","author":"A Moustakas","year":"2007","unstructured":"Moustakas, A. & Heldin, C. H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98, 1512\u20131520 (2007).","journal-title":"Cancer Sci."},{"key":"1101_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2183\/pjab.85.314","volume":"85","author":"K Miyazono","year":"2009","unstructured":"Miyazono, K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 85, 314\u2013323 (2009).","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"1101_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2144\/000112776","volume":"44","author":"HD VanGuilder","year":"2008","unstructured":"VanGuilder, H. D., Vrana, K. E. & Freeman, W. M. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques 44, 619\u2013626 (2008).","journal-title":"Biotechniques"},{"key":"1101_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-357","volume":"9","author":"PA Videira","year":"2009","unstructured":"Videira, P. A. et al. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 9, 357 (2009).","journal-title":"BMC Cancer"},{"key":"1101_CR33","doi-asserted-by":"publisher","first-page":"26474","DOI":"10.1074\/jbc.M213223200","volume":"278","author":"S Saito","year":"2003","unstructured":"Saito, S. et al. Humanalpha2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase. J. Biol. Chem. 278, 26474\u201326479 (2003).","journal-title":"J. Biol. Chem."},{"key":"1101_CR34","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/labinvest.2016.50","volume":"96","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1. Lab. Invest. 96, 731\u2013740 (2016).","journal-title":"Lab. Invest."},{"key":"1101_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/gyno.2001.6358","volume":"83","author":"PH Wang","year":"2001","unstructured":"Wang, P. H. et al. Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix. Gynecol. Oncol. 83, 121\u2013127 (2001).","journal-title":"Gynecol. Oncol."},{"key":"1101_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ygyno.2005.07.016","volume":"99","author":"PH Wang","year":"2005","unstructured":"Wang, P. H. et al. Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol. Oncol. 99, 631\u2013639 (2005).","journal-title":"Gynecol. Oncol."},{"key":"1101_CR37","doi-asserted-by":"crossref","first-page":"29013","DOI":"10.18632\/oncotarget.15994","volume":"8","author":"KC Wen","year":"2017","unstructured":"Wen, K. C. et al. alpha2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells. Oncotarget 8, 29013\u201329027 (2017).","journal-title":"Oncotarget"},{"key":"1101_CR38","doi-asserted-by":"publisher","first-page":"e0136893","DOI":"10.1371\/journal.pone.0136893","volume":"10","author":"ML Granados","year":"2015","unstructured":"Granados, M. L., Hudson, L. G. & Samudio-Ruiz, S. L. Contributions of the epidermal growth factor receptor to acquisition of platinum resistance in ovarian cancer cells. PLoS ONE 10, e0136893 (2015).","journal-title":"PLoS ONE"},{"key":"1101_CR39","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.1507329112","volume":"112","author":"HY Yen","year":"2015","unstructured":"Yen, H. Y. et al. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc. Natl Acad. Sci. USA 112, 6955\u20136960 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1101_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tjog.2018.02.015","volume":"57","author":"PL Sung","year":"2018","unstructured":"Sung, P. L. et al. The role ofalpha2,3-linked sialylation on clear cell type epithelial ovarian cancer. Taiwan J. Obstet. Gynecol. 57, 255\u2013263 (2018).","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"1101_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0092-8674(91)90143-M","volume":"66","author":"K Vleminckx","year":"1991","unstructured":"Vleminckx, K., Vakaet, L. Jr., Mareel, M., Fiers, W. & van Roy, F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66, 107\u2013119 (1991).","journal-title":"Cell"},{"key":"1101_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11010-009-0147-9","volume":"331","author":"S Huang","year":"2009","unstructured":"Huang, S., Day, T. W., Choi, M. R. & Safa, A. R. Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity. Mol. Cell. Biochem. 331, 81\u201388 (2009).","journal-title":"Mol. Cell. Biochem."},{"key":"1101_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fonc.2016.00158","volume":"6","author":"LM da Fonseca","year":"2016","unstructured":"da Fonseca, L. M. et al. Glycosylation in cancer: interplay between multidrug resistance and epithelial-to-mesenchymal transition? Front. Oncol. 6, 158 (2016).","journal-title":"Front. Oncol."},{"key":"1101_CR44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/15592294.2016.1241932","volume":"11","author":"G Greville","year":"2016","unstructured":"Greville, G., McCann, A., Rudd, P. M. & Saldova, R. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer. Epigenetics 11, 845\u2013857 (2016).","journal-title":"Epigenetics"},{"key":"1101_CR45","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/glycob\/cwq085","volume":"20","author":"G Picco","year":"2010","unstructured":"Picco, G. et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 20, 1241\u20131250 (2010).","journal-title":"Glycobiology"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1101-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1101-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1101-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T09:58:02Z","timestamp":1672653482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1101-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1101-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"25 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1102"}}